This study is not yet accepting patients
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startedcompletion around
- Principal Investigator
- by Hyunseok Kang
Description
Summary
Official Title
Details
Keywords
Eligibility
Lead Scientist at UCSF
- Hyunseok Kang
Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- SCG Cell Therapy Pte. Ltd.
- ID
- NCT06505551
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 66 study participants
- Last Updated